drugset
drugset / Trial / NCT05677035

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LINO-1713 in Healthy Korean Female Subjects

NCT05677035 ↗

Phase 1 Completed 20 enrolled Hyundai Pharm
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A single-center, open-label, parallel-group, phase 1 study to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of LINO-1713 in healthy Korean female subjects

Timeline

Start
2022-01-11
Primary completion
2022-06-15
Completion
2022-06-15

Drugs

EvaluationDrugModalityDoseRoute
Subject ESTETROL ANHYDROUS Other / unclassified 15 mg Oral
Subject drospirenone Unknown 3 mg Oral

Indications

No indication recorded.